Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29553142 | 1.00 | NCOA1 (0.51) | NCOA1NCOA3LTA4HPTGS2MAOA | |
| SCHEMBL11521654 | 0.90 | LTA4H (0.58) | LTA4HPTGS2ALDH1A1ARLPAR1 | |
| SCHEMBL17783722 | 0.88 | GAA (0.54) | NCOA1NCOA3LTA4HPTGS2MAOA | |
| SCHEMBL721404 | 0.86 | NCOA1 (0.49) | NCOA1NCOA3LTA4HPTGS2MAOA | |
| SCHEMBL17783721 | 0.85 | LTA4H (0.41) | NCOA1NCOA3LTA4HPTGS2MAOA | |
| SCHEMBL1676646 | 0.84 | LTA4H (0.53) | LTA4HPTGS2TSHRARKMT2A | |
| SCHEMBL14677727 | 0.83 | LTA4H (0.52) | LTA4HPTGS2ALDH1A1TSHRAR | |
| SCHEMBL5583602 | 0.83 | NCOA1 (0.46) | NCOA1NCOA3LTA4HPTGS2MAOA | |
| SCHEMBL8761225 | 0.82 | NCOA1 (0.40) | NCOA1NCOA3LTA4HPTGS2MAOA | |
| SCHEMBL8762110 | 0.82 | NCOA1 (0.40) | NCOA1NCOA3LTA4HPTGS2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| US-11286359-B2 | Prepreg and carbon fiber-reinforced composite material | TORAY INDUSTRIES, INC. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-11111345-B2 | Prepreg and carbon fiber-reinforced composite material | TORAY INDUSTRIES, INC. (JP) | 2021-09-07 | — | — | US | disclosed |
| CN-110191915-B | Prepreg, method for producing same, and slit tape prepreg | 东丽株式会社 | 2021-07-23 | — | — | CN | disclosed |
| EP-3800285-A1 | SIZING-AGENT-COATED CARBON FIBRE BUNDLE, CARBON-FIBRE-BUNDLE PRODUCTION METHOD, AND PREPREG | Toray Industries, Inc. (JP) | 2021-04-07 | — | — | EP | disclosed |
| CN-112313078-A | Prepreg, method for producing prepreg, slit tape prepreg, and carbon fiber-reinforced composite material | 东丽株式会社 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019141980-A1 | AGRICULTURAL CHEMICALS | GLOBACHEM NV (BE) | 2019-07-25 | — | — | WO | disclosed |
| US-10184034-B2 | Carbon fiber forming raw material, formed material, and carbon fiber-reinforced composite material | TORAY INDUSTRIES, INC. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-10138593-B2 | Sizing agent-coated carbon fibers, process for producing sizing agent-coated carbon fibers, prepreg, and carbon fiber reinforced composite material | TORAY INDUSTRIES, INC. (JP) | 2018-11-27 | — | — | US | disclosed |
| US-8263216-B2 | Epoxy resin composition for fiber-reinforced composite material, prepreg, and fiber-reinforced composite material | TORAY INDUSTRIES, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20120035299-A1 | EPOXY RESIN COMPOSITION FOR FIBER-REINFORCED COMPOSITE MATERIAL, PREPREG, AND FIBER-REINFORCED COMPOSITE MATERIAL | TORAY INDUSTRIES, INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| EP-2412742-A1 | EPOXY RESIN COMPOSITION FOR FIBER-REINFORCED COMPOSITE MATERIAL, PREPREG, AND FIBER-REINFORCED COMPOSITE MATERIAL | Toray Industries, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2341092-A1 | EPOXY COMPOUND AND MANUFACTURING METHOD THEREOF | Toray Fine Chemicals Co., Ltd. (JP) | 2011-07-06 | — | — | EP | disclosed |
| US-20110040111-A1 | EPOXY COMPOUND AND MANUFACTURING METHOD THEREOF | TORAY FINE CHEMICALS CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| US-6953807-B2 | 4-substituted-picolinic acid amide derivatives useful as fungicides | BAYER CROPSCIENCE S.A. (FR) | 2005-10-11 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040111-A1 | EPOXY COMPOUND AND MANUFACTURING METHOD THEREOF | CYP2E1, CYP4A11, CYP1A1 | NCOA1 186/4885NCOA3 403/4885LTA4H 154/4885 |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | NCOA1 3470/4885NCOA3 3719/4885LTA4H 615/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | NCOA1 1434/4885NCOA3 1627/4885LTA4H 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.